Fight Colorectal Cancer shared a post on X:
“New FDA approval: atezolizumab plus chemo for stage III dMMR colon cancer after surgery.
ATOMIC trial: risk of recurrence or death cut in HALF (86% vs 76% cancer-free at 3 yrs).
It only applies to dMMR/MSI-H tumors — and the only way to know is a Biomarker Test.
What to ask your care team plus how to understand your results.”
Source: FDA.”
You can also read: FDA Approved Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
